Related Experiment Video

Updated: Jan 28, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K

New proteasome inhibitors in the treatment of multiple myeloma

Vania Tietsche de Moraes Hungria1, Edvan de Queiroz Crusoé2, Rosane Isabel Bittencourt3

  • 1Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.

Hematology, Transfusion and Cell Therapy
|February 23, 2019
PubMed

Insights

New proteasome inhibitors offer improved progression-free survival for multiple myeloma patients. These agents show promise in managing high-risk cases, potentially changing treatment paradigms.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma treatment has advanced significantly with proteasome inhibitors and immunomodulatory drugs.
  • Recent clinical trials show improved outcomes with novel proteasome inhibitors.

Purpose of the Study:

  • To review the pharmacological properties and clinical outcomes of new proteasome inhibitors.
  • To discuss the potential impact of these agents on multiple myeloma treatment.

Main Methods:

  • Review of clinical trial data and pharmacological studies.
  • Analysis of progression-free survival and safety profiles.
  • Evaluation of health-related quality of life data.

Main Results:

  • Triplet regimens with new proteasome inhibitors demonstrate superior progression-free survival compared to standard doublet regimens.
  • These new agents exhibit acceptable safety profiles.
  • Health-related quality of life is maintained or improved with novel treatment regimens.

Conclusions:

  • New proteasome inhibitors represent a significant advancement in multiple myeloma therapy.
  • These agents have the potential to address unmet needs, particularly in high-risk patient populations.
  • The evolving therapeutic landscape for multiple myeloma is being reshaped by these innovative treatments.
Keywords:
BortezomibCarfilzomibIxazomibMultiple myelomaProteasome inhibitors

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.7K

Related Concept Videos

The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.2K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.7K
The Proteasome02:18

The Proteasome

4.6K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
595
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
1.7K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K